# Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition

## TL;DR

This study shows that pre-existing CD95-based Temra immunity in nasopharyngeal cancer patients can predict treatment response and hyperprogression when using dual PD-L1 and TGFβ inhibition.

## Contribution

The novel contribution is identifying CD95 and CD57 Temra markers as predictors of treatment outcomes and hyperprogression risk in nasopharyngeal carcinoma patients.

## Key findings

- Lower baseline CD95⁺ Temra levels correlate with treatment response and longer survival.
- Higher CD57⁺ Temra frequencies are linked to improved overall survival.
- Post-treatment CD95/CD57 expression shifts correlate with survival outcomes.

## Abstract

None.

• Lower baseline CD95⁺ Temra levels were associated with treatment response and longer survival.

• Higher CD57⁺ Temra frequencies predicted improved overall survival, independent of response.

• Post‐treatment shifts in CD95/CD57 expression correlated with survival outcomes.

• TGFβlow/CD95⁺ Temra high profile identified non‐responders with hyperprogression risk.